An orally-active, next-generation S1P1 agonist in clinical development for autoimmune diseases. Data from completed Phase 1b study demonstrated best-in-class potential with rapid onset of T cell modulation at an extremely low dose and excellent safety and tolerability. Phase 2 studies of CBP-307 in IBD will begin in Q2, 2018.
Learn More>>A highly potent monoclonal antibody against IL-4Rα, a receptor for both IL-4 and IL-13, two key Th2 cytokines that drive allergic inflammatory diseases. CBP-201 is currently in preclinical development as a treatment several diseases, including atopic dermatitis, asthma, and COPD. IND filing is expected in Q1, 2018.
Learn More>>A small molecule inhibitor of a G-protein coupled receptor involved in pruritus associated with chronic skin inflammation. It is highly efficacious in preclinical pruritus models via a novel mechanism of action and thus has the potential to be first of a new class of anti-pruritus drug. Preclinical development is currently underway.
Learn More>>Connect Biopharmaceuticals is a China-based global clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our drug discovery technology platform is built on the biology of T cell functions, which identifies molecules that target clinical-validated disease pathways.
